The Burrill Report (June 23, 2014): Monoclonal Antibodies Going to the Dogs (and Cats). (.MP3,12.66 Mb)
Nexvet is a global biotechnology company developing monoclonal antibodies, but what makes it unusual is that it’s developing these therapeutics for pets. Nexvet’s platform technology can take a human monoclonal antibody and customize it to target a new species, such as cats and dogs. We spoke to Mark Heffernan, CEO of Nexvet, about the $25 billion global animal health drug market, the company’s technology, and why he expects his products to be cost competitive.June 19, 2014
http://www.burrillreport.com/article-monoclonal_antibodies_going_to_the_dogs_and_cats.html